Cardiovascular effects of anti-obesity medications: the perils and promise DOI Creative Commons
Haoyi Zheng

Cardiology Plus, Journal Year: 2025, Volume and Issue: unknown

Published: March 18, 2025

Anti-obesity medications have gone through a tumultuous course of approvals and withdrawals, often triggered by serious cardiovascular complications. Early agents, including amphetamines fenfluramine–phentermine, were once widely used but ultimately banned or voluntarily withdrawn due to Sibutramine followed similar trajectory when clinical trials revealed increased event rates, prompting its market withdrawal. Lorcaserin, initially promising for weight management without significant risks, was after postmarketing surveillance potential link cancer incidence. Although more recent medications, orlistat, phentermine–topiramate, naltrexone–bupropion, remain available, their cardiometabolic benefits are modest, long-term outcome data inconclusive still lacking. The emergence glucagon-like peptide 1 (GLP-1) receptor agonists co-agonists has transformed obesity management. Liraglutide, semaglutide, tirzepatide, originally developed type 2 diabetes, demonstrated substantial sustained loss along with notable improvements in markers. In high-risk populations, randomized liraglutide semaglutide also shown reductions major adverse events. Moreover, tirzepatide exhibited patients heart failure preserved ejection fraction obesity. Overall, GLP-1 hold promise, however, questions regarding safety effects broader populations. history approval withdrawal anti-obesity underscores the importance surveillance. As evidence continues accumulate, balance between efficacy will guide optimal use both risk reduction.

Language: Английский

Tirzepatide for Obesity Treatment and Diabetes Prevention DOI
Ania M. Jastreboff, Carel W. le Roux, Adam Stefański

et al.

New England Journal of Medicine, Journal Year: 2024, Volume and Issue: unknown

Published: Nov. 13, 2024

BackgroundObesity is chronic disease and causal precursor to myriad other conditions, including type 2 diabetes. In an earlier analysis of the SURMOUNT-1 trial, tirzepatide was shown provide substantial sustained reductions in body weight persons with obesity over a 72-week period. Here, we report 3-year safety outcomes its efficacy reducing delaying progression diabetes both prediabetes.MethodsWe performed phase 3, double-blind, randomized, controlled trial which 2539 participants obesity, whom 1032 also had prediabetes, were assigned 1:1:1:1 ratio receive at once-weekly dose 5 mg, 10 or 15 mg placebo. The current involved who received their placebo for total 176 weeks, followed by 17-week off-treatment three key secondary end points, I error, percent change from baseline week onset during 176-week 193-week periods.ResultsAt mean among −12.3% 5-mg dose, −18.7% 10-mg −19.7% 15-mg as compared −1.3% those (P<0.001 all comparisons placebo). Fewer diagnosis groups than group (1.3% vs. 13.3%; hazard ratio, 0.07; 95% confidence interval [CI], 0.0 0.1; P<0.001). After 17 weeks off treatment placebo, 2.4% 13.7% (hazard 0.12; CI, 0.1 0.2; Other coronavirus 2019, most common adverse events gastrointestinal, mild moderate severity occurred primarily dose-escalation period first 20 trial. No new signals identified.ConclusionsThree years prediabetes resulted reduction markedly lower risk that (Funded Eli Lilly; ClinicalTrials.gov number, NCT04184622.)

Language: Английский

Citations

45
The impact of weight loss on fat-free mass, muscle, bone and hematopoiesis health: Implications for emerging pharmacotherapies aiming at fat reduction and lean mass preservation DOI
Konstantinos Stefanakis, Michail Kokkorakis, Christos S. Mantzoros

et al.

Metabolism, Journal Year: 2024, Volume and Issue: unknown, P. 156057 - 156057

Published: Oct. 1, 2024

Language: Английский

Citations

15
Mechanistic insights into GLP-1 receptor agonist-induced weight loss through ceRNA network analysis DOI Creative Commons
Wenxin Li, Xinyu Zhang, Jiamin Song

et al.

Genomics, Journal Year: 2025, Volume and Issue: 117(2), P. 110988 - 110988

Published: Jan. 5, 2025

GLP-1 receptor agonists (GLP-1RA) have been extensively utilized in the management of body weight individuals with obesity. Circular RNA (circRNA), a class covalently closed molecules, has garnered increasing attention for its potential role pathogenesis However, specific mechanisms through which circRNA contributes to GLP-1RA-induced loss remains elusive. High-throughput sequencing analyzed epididymal adipose tissue from obese mice under high-fat, and GLP-1RA intervention (600 μg/kg/d). The functions differentially expressed (DE) genes were enriched analyzed. circRNA-miRNA-mRNA interaction network was constructed Cytoscape, KEGG pathway gene enrichment validated via western blotting. A total 644 DEcircRNAs, 186 DEmiRNAs, 3474 DEmRNAs identified. Based on ceRNA score calculations, diagrams constructed. Gene Ontology (GO) analysis revealed that DERNAs linked lipid fatty acid metabolism. DE within pairs metabolism pathways, especially PI3K-Akt AMPK signaling pathways. induced phosphorylation AKT AMPK, subsequently led reduction SREBP-1, ACC, FAS. might activate pathways combat obesity circRNAs.

Language: Английский

Citations

1
Conjugated polymer of Multi-arm-PEG and dimethylsiloxane (CPMD) for the effective transdermal delivery of deoxycholic acid for fat reduction DOI Creative Commons
Hwajun Jeong, H.K. Kim,

H. Kim

et al.

Chemical Engineering Journal, Journal Year: 2025, Volume and Issue: unknown, P. 159405 - 159405

Published: Jan. 1, 2025

Language: Английский

Citations

1
Therapeutic Advances in Obesity: How Real-World Evidence Impacts Affordability Beyond Standard of Care DOI Creative Commons
Dimitrios Patoulias, Theocharis Koufakis,

Ieva Ruža

et al.

Pragmatic and Observational Research, Journal Year: 2024, Volume and Issue: Volume 15, P. 139 - 149

Published: Aug. 1, 2024

Obesity is currently considered a global epidemic, with rising prevalence worldwide and rather pessimistic projections. Based on its close interconnection various co-morbidities, such as diabetes mellitus cardiovascular disease, obesity associated significant increases in morbidity mortality, while it also poses substantial economic burden for national healthcare systems. Apparently, the majority of individuals classified obese do not achieve adequate weight loss adoption healthy lifestyle intervention, including dietary modification physical activity. Fortunately, during last decade, progress pharmacotherapy has been observed, introduction agents that have gained approval from regulatory authorities, namely semaglutide, liraglutide tirzepatide, due to their impressive results body reduction, alongside beneficial, pleiotropic effects. The aim present review article discuss evidence retrieved real-world studies regarding efficacy those treatment, emphasis cost-effectiveness data, towards an effort tackle efficiently progression epidemic.

Language: Английский

Citations

5
Navigating obesity: A comprehensive review of epidemiology, pathophysiology, complications and management strategies DOI

Ning Xiao,

Yi Ding, Bing Cui

et al.

The Innovation Medicine, Journal Year: 2024, Volume and Issue: 2(3), P. 100090 - 100090

Published: Jan. 1, 2024

<p>Obesity, a growing global health crisis, is driven by complex interplay of genetic, biological, environmental, behavioral, socio-cultural, and economic factors. This comprehensive review encapsulates the epidemiology, pathophysiological mechanism, myriad complications it triggers, such as cardiovascular diseases (CVDs), cancer, neurological disorders, respiratory ailments, digestive diseases, mobility impairments, psychological stress. The etiology obesity multifaceted, involving genetic predispositions, environmental influences, behavioral tendencies, socio-economic elements. underpinnings encompass multifaceted aspects energy metabolism, including regulation appetite, glucose, lipid, amino acid metabolism. also addresses seemingly contradictory roles in various offering insights into these phenomena. management multi-pronged, lifestyle modifications, pharmacological interventions, metabolic surgeries. Lifestyle changes are foundational, but advancements molecular techniques, digital technology, wearable devices, artificial intelligence opening new avenues for personalized treatment early intervention. Pharmacological surgery effective should be judiciously tailored to individual patient needs. underscores importance approach management, aiming curb escalating trend enhance future interventions treatments. ultimate goal synthesize current evidence innovative strategies combat effectively.</p>

Language: Английский

Citations

5
Moderate static magnetic field modulated lipid metabolism abnormalities induced by continuous artificial light in Caenorhabditis elegans: Role of iron ions DOI Creative Commons

Baolin Yang,

Lei Cheng, Yang Li

et al.

Ecotoxicology and Environmental Safety, Journal Year: 2025, Volume and Issue: 292, P. 117959 - 117959

Published: Feb. 28, 2025

Excessive use of artificial light sources has led to a significant increase in pollution, which raised serious concerns due its adverse effects on lipid metabolism. Although moderate static magnetic fields (SMFs) have shown potential health intervention and treatment as non-invasive highly permeable physical field, the influence SMFs metabolic disturbance induced by lights remains largely unknown. In this study, we explored metabolism Caenorhabditis elegans (C. elegans) under varying wavelengths ranging from 395 nm 635 nm, both presence absence 0.5 T SMF, elucidated their underlying mechanisms. Exposure C. at 200 lux resulted shortened lifespan while significantly increasing fat accumulation wavelength-dependent manner. The SMF extended reduced size droplets, well content triglyceride exposed worms. These were achieved upregulating expression genes related lipolysis downregulating synthesis. Moreover, alleviated abnormalities caused through regulation iron ions. Our findings provided clear evidence that protective via mediating homeostasis, might contribute better understanding combined photomagnetic living organisms.

Language: Английский

Citations

0
Trends in the use of drugs with weight‐loss effect: Scandinavian study from 2017 to 2023 DOI
Paz Lopez‐Doriga Ruiz,

Lars Bakke Hindenes,

Øystein Karlstad

et al.

Diabetes Obesity and Metabolism, Journal Year: 2025, Volume and Issue: unknown

Published: Feb. 27, 2025

Language: Английский

Citations

0
The promise of glucagon-like peptide 1 receptor agonists (GLP-1RA) for the treatment of obesity: a look at phase 2 and 3 pipelines DOI Creative Commons
Sten Madsbad, Jens J. Holst

Expert Opinion on Investigational Drugs, Journal Year: 2025, Volume and Issue: unknown, P. 1 - 19

Published: March 1, 2025

Introduction GLP-1-based therapies have changed the treatment of overweight/obesity. Liraglutide 3.0 mg daily, first GLP-1 RA approved for overweight, induced a weight loss 6–8%, Semaglutide 2.4 once weekly improved to about 12–15%, while dual GIP/GLP-1 receptor agonist tirzepatide has 20% in obese people without diabetes.

Language: Английский

Citations

0
Recent Progress in the Management of Obesity: Advances and Insights from the Latest Research DOI Open Access
Javier Gómez‐Ambrosi

Nutrients, Journal Year: 2025, Volume and Issue: 17(7), P. 1225 - 1225

Published: March 31, 2025

The field of obesity research continues to evolve rapidly, driven by new insights into metabolic regulation, behavioral interventions, and disparities in treatment outcomes [...].

Language: Английский

Citations

0